Article

Mortality data emerge from AREDS

Valuable new data continue to be gleaned from the Age-Related Eye Disease Study (AREDS). In this large randomized, controlled clinical study of 4,753 patients, investigators at 11 sites evaluated the effect of antioxidants vitamins C and E and zinc compared with placebo in age-related macular degeneration (AMD).

New Orleans-Valuable new data continue to be gleaned from the Age-Related Eye Disease Study (AREDS). In this large randomized, controlled clinical study of 4,753 patients, investigators at 11 sites evaluated the effect of antioxidants vitamins C and E and zinc compared with placebo in age-related macular degeneration (AMD). The patients were divided by disease severity into categories 1-4 , with category 1 indicating the presence of few if any small drusen and category 4 indicating the most severe form of AMD, unilateral advanced disease, or unilateral visual loss worse than 20/32.

The investigators evaluated all-cause mortality in 534 of the patients who died between November 1992 and October 2001. Justin Gottlieb, MD, from the University of Wisconsin, Madison, reported, All-cause mortality rates increased with increasing severity of macular disease. AMD category 4 compared with AMD category 1 had a significantly increased risk of mortality after adjustment for age, sex, race, education, smoking, body mass index, diabetes, angina, cancer, and hypertension. All-cause mortality decreased for participants.

In addition, most of the deaths resulted from circulatory system pathologies and neoplasms (68%). Zinc did not show a protective effect against those disorders, but a protective effect was seen for other causes. The investigators, who presented their data at the retina subspecialty day at the American Academy of Ophthalmology annual meeting, speculated that zinc might improve immunity and resistance to infection.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.